Serotonin Norepinephrine Reuptake Inhibitors and the Risk of Serious Adverse Events

Risk of Serious Adverse Events Associated With Serotonin Norepinephrine Reuptake Inhibitors Use in Older Adults, With a Focus on Chronic Kidney Disease.

This is a population-based retrospective, new-user design, active comparator cohort study assessing whether initiating a new outpatient prescription of high-dose serotonin norepinephrine reuptake inhibitors (SNRIs)-venlafaxine (>37.5-150 mg/day) or duloxetine (>30-120 mg/day), compared with low-dose SNRIs- venlafaxine (37.5 mg/day) or duloxetine (30 mg/day), is associated with an increased 30-day risk of serious adverse events among older adults with low kidney function (estimated glomerular filtration rate [eGFR] <45 ml/min/1.73m2) who are not receiving dialysis and have no history of kidney transplantation.

The primary outcome is a 30-day composite of all-cause emergency department visit, all-cause hospitalization, or all-cause mortality.

Study Overview

• Status: Completed
• Conditions: Chronic Kidney Disease
• Intervention / Treatment: Drug: Venlafaxine or duloxetine

Detailed Description

Venlafaxine and duloxetine are serotonin norepinephrine reuptake inhibitors (SNRIs) commonly prescribed in older adults for depression, anxiety, and neuropathic pain.

Both medications are metabolized in the liver, and their elimination involves the renal route. The clearance of venlafaxine and duloxetine may be decreased in patients with low kidney function, leading to increased systemic exposure. Venlafaxine and duloxetine use in older adults with low kidney function may increase the risk of developing serious adverse events.

The most common measure to assess kidney function in routine clinical care is the estimated glomerular filtration rate (eGFR), expressed in lab reports as mL/min/1.73 m2. A normal eGFR is >90 mL/min/1.73 m2, and a value <45 mL/min/1.73 m2 is considered to be low.

The investigators aim to conduct a population-based cohort study among older adults with low kidney function in Ontario, comparing the risk of serious adverse events among those initiating high-dose SNRIs-venlafaxine (>37.5-150 mg/day) or duloxetine (>30-120 mg/day), versus low-dose SNRIs-venlafaxine (37.5 mg/day) or duloxetine (30 mg/day) in the outpatient setting. Secondary analyses will evaluate low-dose venlafaxine (37.5 mg/day) versus low-dose duloxetine (30 mg/day) and high versus lower doses within each drug.

Methods:

In this population-based retrospective cohort study, eligible participants will include older adults (≥66 years) with eGFR <45 mL/min/1.73 m² (not receiving dialysis or having a history of kidney transplantation) from Ontario who were dispensed a new outpatient prescription for oral venlafaxine or duloxetine. In Ontario, accrual will occur between January 1, 2008, and December 1, 2025.

Based on the prescribed daily dose at treatment initiation, individuals initiating venlafaxine will be categorized into two groups: low-dose (37.5 mg/day) and high-dose (>37.5-150 mg/day). Similarly, participants initiating duloxetine will be categorized as low-dose (30 mg/day) and high-dose (>30-120 mg/day) groups.

Propensity score weighting will be used to ensure both groups are well-balanced on a comprehensive set of measured baseline characteristics, including the dose category at treatment initiation. Separate propensity score models will be developed for the secondary analyses.

The primary outcome will be a 30-day composite of all-cause emergency department visit, hospitalization, or mortality.

*Background* Venlafaxine and duloxetine are serotonin-norepinephrine reuptake inhibitors commonly prescribed in older adults with low kidney function for major depressive disorder, anxiety, and neuropathic pain, across a range of daily doses. Serious adverse events associated with venlafaxine and duloxetine reported in the literature include hyponatremia, cardiac arrhythmias, hypotension, falls, and central nervous system-related adverse events such as delirium.

Overall, safety data on SNRIs (venlafaxine and duloxetine) in patients with low kidney function are limited, highlighting the need for a population-based study to assess their real-world safety profiles and inform better care.

Understanding the comparative and dose-specific risks of initiating SNRIs in older adults with low kidney function may help inform safer prescribing and improve clinical outcomes in this population.

*Objective* Is there a higher 30-day risk of a composite outcome of all-cause emergency department visit, all-cause hospitalization, or all-cause mortality among older adults with low kidney function (an eGFR <45 mL/min per 1.73 m2 but not receiving dialysis or having a history of kidney transplantation) who initiate high-dose (venlafaxine >37.5-150 mg/day or duloxetine >30-120 mg/day) versus low-dose (venlafaxine 37.5 mg/day or duloxetine 30 mg/day) SNRIs in the outpatient setting?

*Study design and setting* The investigators propose a population-based retrospective cohort study using linked administrative health data from Ontario. If the Ontario cohort is too small to generate reliable estimates, the investigators will augment the study by performing an analysis using Alberta health administrative data.

Ontario data will be sourced from ICES (Institute for Clinical Evaluative Sciences; ices.on.ca). It offers secure, encrypted individual-level data for Ontario residents, all with universal access to hospital and physician services under a government-funded, single-payer healthcare system. The use of data in this study is authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a research ethics board. The information needed to analyze the primary outcomes is available across specific databases within the ICES system: data on all-cause hospitalizations are available in the Canadian Institute for Health Information Discharge Abstract Database, emergency department visits are captured in the National Ambulatory Care Reporting System, and mortality is available in the Registered Persons Database.

If the investigators proceed with conducting the study in Alberta and combining the findings with Ontario, the Alberta data will be accessed through the Alberta Kidney Disease Network; this dataset ends in ~ 2021.

The investigators are publicly registering the study protocol and documenting the study description, design, and statistical analysis prior to conducting outcome analyses. The results of this study will be reported adhering to the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) reporting guidelines.

*Study Population* The investigators will include all older adults (≥66 years) with an eGFR <45 mL/min per 1.73 m2 (not receiving dialysis or having a history of kidney transplantation) who received a new outpatient prescription for oral venlafaxine or duloxetine. The dispensing date of the prescription will serve as the index date. Only the first eligible prescription will be included to ensure unique cohort entry; each individual may enter the cohort only once.

*Baseline Characteristics* Health records, census files, hospital discharge records, laboratory data, and physician claims will provide baseline variables, including demographic characteristics (such as age, sex, rurality, neighborhood income quintile, etc.), comorbidities, and medication use. Baseline comorbidities and healthcare utilization will be assessed using 5-year and 1-year look-back periods from the index date. Baseline medication use will be assessed within 120 days prior to the index date.

*Statistical analysis plan* Categorical variables will be summarized as frequencies and proportions, while continuous variables will be summarized as means with standard deviations (SDs) or medians with interquartile ranges (IQRs), as appropriate.

Baseline characteristics will be compared between exposure groups using standardized mean differences (SMDs), with an absolute SMD greater than 10% considered indicative of a meaningful imbalance. This approach will be used for the primary comparison between high-dose (venlafaxine >37.5-150 mg/day and duloxetine >30-120 mg/day) and low-dose SNRIs (venlafaxine 37.5mg/day and duloxetine 30mg/day ), as well as for secondary comparisons of low-dose venlafaxine (37.5 mg/day) versus low-dose duloxetine (30 mg/day), and between high-dose and low-dose within each drug.

Balancing comparator group: The investigators will use inverse probability of treatment weighting (IPTW) on the propensity score to balance baseline characteristics between the exposure groups, including predictors of venlafaxine and duloxetine use.

Propensity scores will be generated using a multivariable logistic regression model with all baseline characteristics.

Average treatment effect in the treated (ATT) weights will be used, with patients in the low-dose SNRI group will be assigned weights of (propensity score / [1 - propensity score]), and patients in the high-dose SNRI group will be assigned a weight of 1. This method produces a weighted pseudo-population in which the distribution of measured baseline characteristics in the low-dose group is similar to that in the high-dose group. Baseline characteristics will be compared between groups using standardized differences in both unweighted and weighted samples.

Regression analysis: To evaluate the primary outcome composite measure of all-cause emergency department visit, all-cause hospitalization, or all-cause mortality, the investigators will apply a modified Poisson regression analysis to estimate the risk ratio (95% confidence intervals) and binomial regression to estimate the risk difference (95% confidence intervals) using the weighted cohort, with the low dose group as the referent.

Secondary analyses:

The investigators will conduct independent testing for all secondary outcomes without adjusting for multiple comparisons. Each outcome will be analyzed and reported independently. In line with best practices, the primary outcome will be presented with its P-value, and the investigators will report all secondary outcomes using point estimates with 95% confidence intervals.

Additional analyses: The investigators plan to conduct seven additional analyses.

1. Effect measure modification (EMM):

   To evaluate EMM, the investigators will expand the cohort to all the eGFR levels and categorize them into three groups: eGFR ≥60, 45-<60, and <45 mL/min/1.73 m2. Baseline characteristics between the high-dose and low-dose SNRIs groups will be assessed using standardized differences for all renal function categories combined, and within each of the three eGFR categories (≥60, 45-<60, and <45 mL/min/1.73 m²).

   To further balance baseline characteristics between the high-dose and low-dose SNRI groups, the investigators will apply the IPTW method (described above), based on propensity scores for all eGFR categories combined and within each of the three eGFR categories.

   EMM on the absolute scale for the primary composite outcome (30-day composite outcome of all-cause emergency department visit, all-cause hospitalization, or all-cause mortality) will be examined across three baseline eGFR categories.

   EMM will be assessed on both the additive and multiplicative scales. For additive interaction, the investigators will use binomial regression with an identity link to estimate risk differences, including an interaction term between high-dose SNRIs and low-dose SNRIs and eGFR strata.

   For multiplicative interaction, the investigators will use modified Poisson regression analysis to estimate risk ratios, including an interaction term between venlafaxine and duloxetine and eGFR strata.

2. Our interest in examining the safety of serotonin norepinephrine reuptake inhibitors (venlafaxine and duloxetine) in older adults with low kidney function is derived from high-throughput computing analysis in which the investigators executed 700+ population-based, new-user cohort studies, each comparing 74 acute (30-day) outcomes across strata of kidney function. In this analysis, venlafaxine and duloxetine were compared against non-users, separately; the investigators found signs of harm, prompting us to undertake the current study. High-throughput analysis was run using Ontario data from January 1, 2008, to March 1, 2020. To confirm results, when there is no overlap, the investigators will perform the analysis restricting the cohort after March 1, 2020.

   Examine whether the association between high-dose SNRIs versus low-dose SNRIs and the primary outcome is different (modified) in 2 period categories (the period before the end date of the high-throughput computing, and the period after the end date of the high-throughput computing).

   The investigators will perform analysis restricted to the non-overlap period, i.e., after March 1, 2020.

3. Compute the hazard ratio for all outcomes within 30 days, illustrating the effect of the intervention on each outcome over time. The investigators expect hazard ratios results similar to risk ratios. Although the difference between hazard ratios and risk ratios may be minimal over a short follow-up period, the hazard ratio offers additional insight by accounting for time-to-event analysis.
4. Compare SNRI users (low-dose and high-dose SNRIs separately) with non-users of SNRIs, separately, to contextualize the magnitude and direction of risk observed in the dose-comparison analysis. This analysis will follow a new-user design and apply propensity score weighting to balance baseline characteristics between study drugs and non-users.
5. The investigators will perform E-value analyses to determine the minimum association strength an unmeasured confounder would need with both the prescription drug and the outcome of interest (while adjusting for measured covariates) to eliminate the observed association.

6. Among patients with low kidney function (eGFR <45 mL/min/1.73 m²), the investigators will conduct prespecified subgroup analyses to examine whether the association between venlafaxine versus duloxetine users and the 30-day primary composite outcome differs across clinically relevant subgroups.

   Subgroups will be defined by baseline eGFR category (30-<45 and <30 mL/min/1.73 m²), baseline long-term care residence, anxiety and depression, dementia, and bipolar disorder. Effect measure modification will be assessed on both the additive and multiplicative scales using interaction terms in weighted regression models.

7. The investigators will conduct additional analyses to examine whether the association with the primary 30-day composite outcome differs across dose-specific groups of SNRIs (venlafaxine and duloxetine) among patients with low kidney function. The planned dose-specific comparisons will include: (i) low-dose venlafaxine versus low-dose duloxetine, (ii) low-dose versus high-dose duloxetine, (iii) low-dose versus high-dose venlafaxine.

   • Combining Outcome Results from Ontario and Alberta* This approach will only be used if the investigators proceed with conducting the analysis in Alberta. Privacy-preserving method: The investigators plan to use a privacy-preserving Cox-based approach to estimate risk ratios in multisite studies where individual-level data cannot be shared due to privacy constraints. The proposed method requires only a single transfer of summary-level outputs from each province to the research team. It produces results identical to those from a corresponding log-binomial regression with combined individual-level data. The method was developed by adapting the risk-set table approach for survival outcomes, assuming stratified, province-specific baseline risks, and allowing confounding mitigation strategies, such as propensity score matching or weighting, to be applied individually in each province. Each province will independently calculate these summary tables using its individual-level data. The summary-level risk-set tables generated in Alberta will be shared in a single data transfer to the coordinating site's analyst, who will use them to estimate the combined risk ratios and 95% confidence intervals. This will enable robust, consistent analysis while maintaining data privacy and ensuring regulatory compliance. To comply with privacy regulations for minimizing the chance of identification of any individual, in all manuscripts, numbers of individuals are suppressed in the case of 5 or fewer participants (reported as ≤5). All team members will sign any required data confidentiality and data use agreements.

• Study Type: Observational
• Enrollment (Actual): 8688

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Adults aged 66 years or older with low kidney function (eGFR <45 mL/min per 1.73 m2 but not receiving dialysis or having a history of kidney transplantation) who have filled a new outpatient prescription of oral venlafaxine or duloxetine between 2008 and 2025 in Ontario.

Description

Inclusion Criteria:

• The cohort will include all older adults (≥66 years) with an eGFR <45 mL/min per 1.73 m2 (not receiving dialysis or having a history of kidney transplantation) who received a new outpatient prescription for oral venlafaxine or duloxetine between January 1, 2008, and December 1, 2025.

The age criterion is set to guarantee that individuals in this population have had at least one year of prior prescription drug coverage. The date when the prescription was filled will serve as the patient's entry or index date for the cohort, with each patient entering the cohort only once.

Exclusion Criteria:

• Individuals with missing administrative database number, missing or invalid age (<0 or >105 years), missing or invalid sex, death on or before the index date, non-Ontario resident (for Ontario data), or non-Alberta residents (for Alberta data).
• Individuals less than 66 years of age on the index date.
• Those with evidence of any study drug prescription 180 days before the index date (to restrict to new users only).
• Individuals with more than one study drug prescription on the index date, as this complicates the ability to ascertain the prescribed dose accurately.
• Evidence of clinically non-meaningful venlafaxine or duloxetine doses (doses that are either too low or too high). The recommended dose range for venlafaxine is 37.5 to 150 mg per day, and for duloxetine is 30 to 120 mg per day.
• Individuals with end-stage renal disease, chronic dialysis, or a kidney transplant prior to the index date.
• Evidence with hospital discharge or emergency department visit in the two days prior to or on the index date to ensure a new outpatient prescription.

Individuals with no serum creatinine lab value in the 0-365 days prior to the index date.

• Individuals with unstable baseline kidney function: If the most recent serum creatinine test prior to the index date was an inpatient test [ER or hospitalization], and there is not at least one 'outpatient' serum creatinine in the year before test date 1, OR If the most recent prior serum creatinine test prior to the index date was an inpatient test [ER or hospitalization], and while there is at least 'outpatient' serum creatinine test in the year before, the most recent outpatient test prior to differs by an eGFR 10 mL/min/1.73 m2 or more from the value on <test date 1>. In Ontario, it has been shown that outpatient serum creatinine measurements in the province, conducted on a single occasion, indicate stable values.
• The investigators restrict to the first prescription in individuals with more than one eligible prescription. The date of this prescription will be the index date (the date from which outcomes start being assessed).

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
High-dose SNRIs-venlafaxine (>37.5-150 mg/day) or duloxetine (>30-120 mg/day); Residents of Ontario, aged 66 years or older with low kidney function (an eGFR <45 mL/min per 1.73 m² but not receiving dialysis or having a history of kidney transplantation) who have filled a new oral prescription for high-dose serotonin norepinephrine reuptake inhibitors-venlafaxine (>37.5-150 mg/day) or duloxetine (>30-120 mg/day) at an outpatient pharmacy under the Ontario Drug Benefit program from January 01, 2008, to December 01, 2025. The date when the prescription was filled will serve as the patient's entry or index date for the cohort, with each patient entering the cohort only once. If the investigators conduct the study in Alberta, the accrual period for Alberta will be determined.	Drug: Venlafaxine or duloxetine; The primary exposure of interest will be oral serotonin norepinephrine reuptake inhibitors-venlafaxine at a dose of >37.5-150 mg/day or duloxetine (30-120 mg/day). For the primary comparison, low-dose serotonin norepinephrine reuptake inhibitors- venlafaxine (37.5 mg/day) or duloxetine (30 mg/day) will serve as the referent group to reduce confounding by indication.; Other Names: duloxetine; venlafaxine
Low-dose SNRIs- venlafaxine (37.5 mg/day) or duloxetine (30 mg/day); Residents of Ontario, aged 66 years or older with low kidney function (an eGFR <45 mL/min per 1.73 m² but not receiving dialysis or having a history of kidney transplantation) who have filled a new oral prescription for low-dose SNRIs- venlafaxine (37.5 mg/day) or duloxetine (30 mg/day) at an outpatient pharmacy under the Ontario Drug Benefit program from January 01, 2008, to December 01, 2025. The date when the prescription was filled will serve as the patient's entry or index date for the cohort, with each patient entering the cohort only once. If the investigators conduct the study in Alberta, the accrual period for Alberta will be determined.	Drug: Venlafaxine or duloxetine; The primary exposure of interest will be oral serotonin norepinephrine reuptake inhibitors-venlafaxine at a dose of >37.5-150 mg/day or duloxetine (30-120 mg/day). For the primary comparison, low-dose serotonin norepinephrine reuptake inhibitors- venlafaxine (37.5 mg/day) or duloxetine (30 mg/day) will serve as the referent group to reduce confounding by indication.; Other Names: duloxetine; venlafaxine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with a 30-day composite outcome of all-cause emergency department visit, all-cause hospitalization, or all-cause mortality.	30-day all-cause emergency department visit, all-cause hospitalization, and all-cause mortality will be combined into a composite measure. Only the first hospitalization or emergency department visit occurring after the cohort entry date will be considered.	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with 30-day all-cause emergency department visit.	One of the components of the primary composite outcome, 30-day all-cause emergency department visit, individually presented as a secondary outcome. Only the first 30-day emergency department visit after the cohort entry date will be considered.	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.
Number of participants with 30-day all-cause hospitalization.	One of the components of the primary composite outcome, 30-day all-cause hospitalization, individually presented as a secondary outcome. Only the first 30-day hospitalization after the cohort entry date will be considered.	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.
Number of participants with 30-day all-cause mortality.	One of the components of the primary composite outcome, 30-day all-cause mortality, individually presented as a secondary outcome.	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.
30-day composite outcome of a hospital encounter with fragility fracture, falls, hypotension, or syncope.	30-day composite outcome of a hospital encounter (emergency department visit or hospital admission) with fragility fracture (hip, femur, humerus, wrist/forearm, pelvis, and spine), falls, hypotension, or syncope.	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.
30-day hospital encounter composite of atrial fibrillation/flutter, ventricular arrhythmia/sudden cardiac death, and other arrhythmia.	30-day hospital encounter (emergency department visit or hospital admission) composite of atrial fibrillation/flutter, ventricular arrhythmia/sudden cardiac death, and other arrhythmia (including pacemaker insertion, palpitations, tachycardia unspecified, atrioventricular block, supraventricular tachycardia, other conduction disorders, implantable cardiac defibrillator).	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.
30-day composite outcome of a hospital encounter with delirium or encephalopathy.	30-day composite outcome of a hospital encounter (emergency department visit or hospital admission) with delirium or encephalopathy (disorientation, transient alteration of awareness, and other unspecified symptoms and signs involving cognitive function) or hospital admission with receipt of an urgent computed tomography scan of the head.	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.
30-day composite outcome of a hospital encounter with heart failure or myocardial infarction, or ischemic stroke.	30-day composite outcome of a hospital encounter (emergency department visit or hospital admission) with heart failure or myocardial infarction (most responsible diagnosis), or ischemic stroke (most responsible diagnosis).	Older adults exposed to high-dose venlafaxine or duloxetine vs low-dose venlafaxine or duloxetine will enter the cohort and will be followed until study outcome (first event), death, or 30 days from the cohort entry date.

Collaborators and Investigators

• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Publications and helpful links

General Publications

• Shu D, Zou G, Hou L, Petrone AB, Maro JC, Fireman BH, Toh S, Connolly JG. A simple Cox approach to estimating risk ratios without sharing individual-level data in multisite studies. Am J Epidemiol. 2025 Jan 8;194(1):226-232. doi: 10.1093/aje/kwae188.
• Abdullah SS, Rostamzadeh N, Muanda FT, McArthur E, Weir MA, Sontrop JM, Kim RB, Kamran S, Garg AX. High-Throughput Computing to Automate Population-Based Studies to Detect the 30-Day Risk of Adverse Outcomes After New Outpatient Medication Use in Older Adults with Chronic Kidney Disease: A Clinical Research Protocol. Can J Kidney Health Dis. 2024 Jan 6;11:20543581231221891. doi: 10.1177/20543581231221891. eCollection 2024.

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2008
• Primary Completion (Actual): December 1, 2025
• Study Completion (Actual): December 31, 2025

Study Registration Dates

• First Submitted: April 9, 2026
• First Submitted That Met QC Criteria: April 9, 2026
• First Posted (Actual): April 15, 2026

Study Record Updates

• Last Update Posted (Actual): April 15, 2026
• Last Update Submitted That Met QC Criteria: April 9, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: older adults; kidney disease; renal failure; duloxetine; venlafaxine; GFR; SNRIs
• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Chronic Disease; Disease Attributes; Pathological Conditions, Signs and Symptoms; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic; Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Lipids; Hydrocarbons; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Amines; Alcohols; Phenethylamines; Ethylamines; Thiophenes; Cyclohexanols; Hexanols; Fatty Alcohols; Duloxetine Hydrochloride; Venlafaxine Hydrochloride
• Other Study ID Numbers: 2026 0906 635 003

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No